Skip to main content
Erschienen in: Digestive Diseases and Sciences 11/2006

01.11.2006 | Original Article

Role of Serum Tumor Markers in Monitoring for Recurrence of Gastric Cancer Following Radical Gastrectomy

verfasst von: Seok Reyol Choi, Jin Seok Jang, Jong Hun Lee, Myung Hwan Roh, Min Chan Kim, Won Sup Lee, Waqar Qureshi

Erschienen in: Digestive Diseases and Sciences | Ausgabe 11/2006

Einloggen, um Zugang zu erhalten

Abstract

It has been suggested that the serum tumor markers AFP, CEA, and CA19-9 may serve as prognostic factors or indicators for recurrence after radical gastrectomy for gastric cancer. We compared the value of these markers in a group with (n=52) and a group without recurrent gastric cancer (n=52) according to the site of recurrence. Serum levels of tumor markers were measured at the time of preoperative diagnosis and at follow-up. At least one tumor marker was positive preoperatively in 20 with recurrence vs. 7 controls (p=0.007). The peritoneum was the most common recurrent site. The positive predictive value of AFP was high at the time of diagnosis and CA19-9 positivity was high at the time of recurrence. Positive CEA suggested recurrence to the liver. In summary, an elevated tumor marker at diagnosis or during follow up may identify patients at higher risk for a recurrence. CA19-9 may be especially useful as a marker for peritoneal recurrence of the gastric cancer, and CEA for recurrence to liver.
Literatur
1.
Zurück zum Zitat Chang YC, Nagasue N, Abe S, Taniura H, Kumar DD, Nakamura T (1992) Comparison between the clinicopathologic features of AFP-positive and AFP-negative gastric cancers. Am J Gastroenterol 87:321–325PubMed Chang YC, Nagasue N, Abe S, Taniura H, Kumar DD, Nakamura T (1992) Comparison between the clinicopathologic features of AFP-positive and AFP-negative gastric cancers. Am J Gastroenterol 87:321–325PubMed
2.
Zurück zum Zitat Mihmanli M, Dilege E, Demir U, Coskun H, Eroglu T, Uysalol MD (2004) The use of tumor markers as predictors of prognosis in gastric cancer. Hepatogastroenterology 51:1544–1547PubMed Mihmanli M, Dilege E, Demir U, Coskun H, Eroglu T, Uysalol MD (2004) The use of tumor markers as predictors of prognosis in gastric cancer. Hepatogastroenterology 51:1544–1547PubMed
3.
Zurück zum Zitat Lukinac L, Bolanca A, Nothig-Hus D, Kusic Z (1997) Follow-up of patients with gastrointestinal cancer by tumor marker determination. Acta Med Croatica 51:73–77PubMed Lukinac L, Bolanca A, Nothig-Hus D, Kusic Z (1997) Follow-up of patients with gastrointestinal cancer by tumor marker determination. Acta Med Croatica 51:73–77PubMed
4.
Zurück zum Zitat Takahashi Y, Takeuchi T, Sakamoto J, Touge T, Mai M, Ohkura H, Kodaira S, Okajima K, Nakazato H (2003) Tumor Marker Committee: the usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study. Gastric Cancer 6:142–145PubMedCrossRef Takahashi Y, Takeuchi T, Sakamoto J, Touge T, Mai M, Ohkura H, Kodaira S, Okajima K, Nakazato H (2003) Tumor Marker Committee: the usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study. Gastric Cancer 6:142–145PubMedCrossRef
5.
Zurück zum Zitat Kono K, Amemiya H, Sekikawa T, Iizuka H, Takahashi A, Fujii H, Matsumoto Y (2002) Clinicopathologic features of gastric cancers producing alpha-fetoprotein. Dig Surg 19:359–365PubMedCrossRef Kono K, Amemiya H, Sekikawa T, Iizuka H, Takahashi A, Fujii H, Matsumoto Y (2002) Clinicopathologic features of gastric cancers producing alpha-fetoprotein. Dig Surg 19:359–365PubMedCrossRef
6.
Zurück zum Zitat Hansen HJ, Snyder JJ, Miller E, Vandevoorde JP, Miller ON, Hines LR, Burns JJ (1974) Carcinoembryonic antigen (CEA) assay. A laboratory adjunct in the diagnosis and management of cancer. Hum Pathol 5:139–147PubMed Hansen HJ, Snyder JJ, Miller E, Vandevoorde JP, Miller ON, Hines LR, Burns JJ (1974) Carcinoembryonic antigen (CEA) assay. A laboratory adjunct in the diagnosis and management of cancer. Hum Pathol 5:139–147PubMed
7.
Zurück zum Zitat Reynoso G, Chu TM, Holyoke D, Cohen E, Nemoto T, Wang JJ, Chuang J, Guinan P, Murphy GP (1972) Carcinoembryonic antigen in patients with different cancers. JAMA 220:361–365PubMedCrossRef Reynoso G, Chu TM, Holyoke D, Cohen E, Nemoto T, Wang JJ, Chuang J, Guinan P, Murphy GP (1972) Carcinoembryonic antigen in patients with different cancers. JAMA 220:361–365PubMedCrossRef
8.
Zurück zum Zitat Nakagoe T, Sawai T, Tsuji T, Jibiki M, Nanashima A, Yamaguchi H, Yasutake T, Ayabe H, Arisawa K, Ishikawa H (2001) Pre-operative serum levels of sialyl Tn antigen predict liver metastasis and poor prognosis in patients with gastric cancer. Eur J Surg Oncol 27:731–739PubMedCrossRef Nakagoe T, Sawai T, Tsuji T, Jibiki M, Nanashima A, Yamaguchi H, Yasutake T, Ayabe H, Arisawa K, Ishikawa H (2001) Pre-operative serum levels of sialyl Tn antigen predict liver metastasis and poor prognosis in patients with gastric cancer. Eur J Surg Oncol 27:731–739PubMedCrossRef
9.
Zurück zum Zitat Marrelli D, Pinto E, De Stefano A, Farnetani M, Garosi L, Roviello F (2001) Clinical utility of CEA, CA 19-9, and CA 72-4 in the follow-up of patients with resectable gastric cancer. Am J Surg 181:16–19PubMedCrossRef Marrelli D, Pinto E, De Stefano A, Farnetani M, Garosi L, Roviello F (2001) Clinical utility of CEA, CA 19-9, and CA 72-4 in the follow-up of patients with resectable gastric cancer. Am J Surg 181:16–19PubMedCrossRef
10.
Zurück zum Zitat Nanashima A, Yamaguchi H, Sawai T, Yamaguchi E, Kidogawa H, Matsuo S, Yasutake T, Tsuji T, Jibiki M, Nakagoe T, Ayabe H (2001) Prognostic factors in hepatic metastases of colorectal carcinoma. Dig Dis Sci 46:1623–1628PubMedCrossRef Nanashima A, Yamaguchi H, Sawai T, Yamaguchi E, Kidogawa H, Matsuo S, Yasutake T, Tsuji T, Jibiki M, Nakagoe T, Ayabe H (2001) Prognostic factors in hepatic metastases of colorectal carcinoma. Dig Dis Sci 46:1623–1628PubMedCrossRef
11.
Zurück zum Zitat Mori M, Sakaguchi H, Akazawa K, Tsuneyoshi M, Sueishi K, Sugimachi K (1995) Correlation between metastatic site, histological type, and serum tumor markers of gastric carcinoma. Hum Pathol 26:504–508PubMedCrossRef Mori M, Sakaguchi H, Akazawa K, Tsuneyoshi M, Sueishi K, Sugimachi K (1995) Correlation between metastatic site, histological type, and serum tumor markers of gastric carcinoma. Hum Pathol 26:504–508PubMedCrossRef
12.
Zurück zum Zitat Nakane Y, Okamura H, Koyanagi N, Boku T, Okusa T, Tanaka K, Hioki K (1994) Correlation of preoperative carcinoembryonic antigen levels and prognosis of gastric cancer patients. Cancer 73:2703–2708PubMedCrossRef Nakane Y, Okamura H, Koyanagi N, Boku T, Okusa T, Tanaka K, Hioki K (1994) Correlation of preoperative carcinoembryonic antigen levels and prognosis of gastric cancer patients. Cancer 73:2703–2708PubMedCrossRef
13.
Zurück zum Zitat Choi JH, Lee SY, Son HY, Hong ES, Kim HJ, Park SY, Hwang MG, Shim KS (1996) Determination of preoperative serum CEA level in curatively resected gastric cancer. J Korean Cancer Assoc 28:1050–1054 Choi JH, Lee SY, Son HY, Hong ES, Kim HJ, Park SY, Hwang MG, Shim KS (1996) Determination of preoperative serum CEA level in curatively resected gastric cancer. J Korean Cancer Assoc 28:1050–1054
14.
Zurück zum Zitat Shimizu N, Wakatsuki T, Murakami A, Yoshioka H, Hamazoe R, Kanayama H, Maeta M, Koga S (1987) Carcinoembryonic antigen in gastric cancer patients. Oncology 44:240–244PubMedCrossRef Shimizu N, Wakatsuki T, Murakami A, Yoshioka H, Hamazoe R, Kanayama H, Maeta M, Koga S (1987) Carcinoembryonic antigen in gastric cancer patients. Oncology 44:240–244PubMedCrossRef
15.
Zurück zum Zitat Maehara Y, Sugimachi K, Akagi M, Kakegawa T, Shimazu H, Tomita M (1990) Serum carcinoembryonic antigen level increases correlate with tumor progression in patients with differentiated gastric carcinoma following noncurative resection. Cancer Res 50:3952–3955PubMed Maehara Y, Sugimachi K, Akagi M, Kakegawa T, Shimazu H, Tomita M (1990) Serum carcinoembryonic antigen level increases correlate with tumor progression in patients with differentiated gastric carcinoma following noncurative resection. Cancer Res 50:3952–3955PubMed
16.
Zurück zum Zitat Santeusanio G, Peronace L, Castagna G, De Muro G, Santi D, D’Orazio A, Amanti C, Midiri G, Campisi C, D’Ambra G (1988) Immunohistochemical study of carcinoembryonic antigen (CEA) in gastric tumor: correlation with preoperative serum levels, histologic type, and grade of anaplasia of the tumor. J Surg Oncol 37:13–19PubMed Santeusanio G, Peronace L, Castagna G, De Muro G, Santi D, D’Orazio A, Amanti C, Midiri G, Campisi C, D’Ambra G (1988) Immunohistochemical study of carcinoembryonic antigen (CEA) in gastric tumor: correlation with preoperative serum levels, histologic type, and grade of anaplasia of the tumor. J Surg Oncol 37:13–19PubMed
17.
Zurück zum Zitat Atkinson BF, Ernst CS, Herlyn M, Steplewski Z, Sears HF, Koprowski H (1982) Gastrointestinal cancer associated antigen in immunoperoxidase assay. Cancer Res 42:4820–4823PubMed Atkinson BF, Ernst CS, Herlyn M, Steplewski Z, Sears HF, Koprowski H (1982) Gastrointestinal cancer associated antigen in immunoperoxidase assay. Cancer Res 42:4820–4823PubMed
18.
Zurück zum Zitat Beretta E, Malesci A, Zerbi A, Mariani A, Carlucci M, Bonato C, Ferrari AM, Di Carlo V (1987) Serum CA 19-9 in the post-surgical follow-up of patients with pancreatic cancer. Cancer 60:2428–2431PubMedCrossRef Beretta E, Malesci A, Zerbi A, Mariani A, Carlucci M, Bonato C, Ferrari AM, Di Carlo V (1987) Serum CA 19-9 in the post-surgical follow-up of patients with pancreatic cancer. Cancer 60:2428–2431PubMedCrossRef
19.
Zurück zum Zitat Herlyn M, Sears HF, Steplewski Z, Koprowski H (1982) Monoclonal antibody detection of a circulating tumor associated antigen. I. Presence of antigen in sera of patients with colorectal, gastric, and pancreatic carcinoma. J Clin Immunol 2:135–140PubMedCrossRef Herlyn M, Sears HF, Steplewski Z, Koprowski H (1982) Monoclonal antibody detection of a circulating tumor associated antigen. I. Presence of antigen in sera of patients with colorectal, gastric, and pancreatic carcinoma. J Clin Immunol 2:135–140PubMedCrossRef
20.
Zurück zum Zitat Imamura Y, Yasutake K, Yoshimura Y, Oya M, Matsushita K, Tokisue M, Ohno S, Masuda T (1990) The changes in tumor markers such as serum CEA, CA 19-9, TPA and CA 125 in the chemotherapy of patients with advanced gastric cancer. Gan To Kagaku Ryoho 17:1501–1507PubMed Imamura Y, Yasutake K, Yoshimura Y, Oya M, Matsushita K, Tokisue M, Ohno S, Masuda T (1990) The changes in tumor markers such as serum CEA, CA 19-9, TPA and CA 125 in the chemotherapy of patients with advanced gastric cancer. Gan To Kagaku Ryoho 17:1501–1507PubMed
21.
Zurück zum Zitat Ritts RE Jr, Del Villano BC, Go VL, Herberman RB, Klug TL, Zurawski VR Jr (1985) Initial clinical evaluation of an immunoradiometric for CA 19-9 using the NCI serum bank. Int J Cancer 33:339–345 Ritts RE Jr, Del Villano BC, Go VL, Herberman RB, Klug TL, Zurawski VR Jr (1985) Initial clinical evaluation of an immunoradiometric for CA 19-9 using the NCI serum bank. Int J Cancer 33:339–345
22.
Zurück zum Zitat Yook JH, Kim BS, Kim YH, Suh BS, Kim WS, Oh ST, Park KC (1999) Diagnostic value of tumor markers in stomach cancer. J Korean Cancer Assoc 31:1094–1100 Yook JH, Kim BS, Kim YH, Suh BS, Kim WS, Oh ST, Park KC (1999) Diagnostic value of tumor markers in stomach cancer. J Korean Cancer Assoc 31:1094–1100
23.
Zurück zum Zitat Kodera Y, Yamamura Y, Torii A, Uesaka K, Hirai T, Yasui K, Morimoto T, Kato T, Kito T (1996) The prognostic value of preoperative serum levels of CEA and CA 19-9 in patients with gastric cancer. Am J Gastroenterol 91:49–53PubMed Kodera Y, Yamamura Y, Torii A, Uesaka K, Hirai T, Yasui K, Morimoto T, Kato T, Kito T (1996) The prognostic value of preoperative serum levels of CEA and CA 19-9 in patients with gastric cancer. Am J Gastroenterol 91:49–53PubMed
24.
Zurück zum Zitat Nishimura H, Okamoto Y, Takahashi M, Fujita T (1976) Occurrence of alpha-fetoprotein, Regan isoenzyme, and variant alkaline phosphatase in the serum of a patient with gastric cancer. Gastroenterology 71:497–499PubMed Nishimura H, Okamoto Y, Takahashi M, Fujita T (1976) Occurrence of alpha-fetoprotein, Regan isoenzyme, and variant alkaline phosphatase in the serum of a patient with gastric cancer. Gastroenterology 71:497–499PubMed
25.
Zurück zum Zitat Ohuchi N, Takahashi K, Matoba N, Sato T, Taira Y, Sakai N, Masuda M, Mori S (1989) Comparison of serum assays for Tag-72, CA 19-9, and CEA in gastrointestinal carcinoma patients. Jpn J Clin Oncol 19:242–248PubMed Ohuchi N, Takahashi K, Matoba N, Sato T, Taira Y, Sakai N, Masuda M, Mori S (1989) Comparison of serum assays for Tag-72, CA 19-9, and CEA in gastrointestinal carcinoma patients. Jpn J Clin Oncol 19:242–248PubMed
Metadaten
Titel
Role of Serum Tumor Markers in Monitoring for Recurrence of Gastric Cancer Following Radical Gastrectomy
verfasst von
Seok Reyol Choi
Jin Seok Jang
Jong Hun Lee
Myung Hwan Roh
Min Chan Kim
Won Sup Lee
Waqar Qureshi
Publikationsdatum
01.11.2006
Erschienen in
Digestive Diseases and Sciences / Ausgabe 11/2006
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-006-9166-5

Weitere Artikel der Ausgabe 11/2006

Digestive Diseases and Sciences 11/2006 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.